Edition:
United Kingdom

Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

626.70INR
10:11am BST
Change (% chg)

Rs7.00 (+1.13%)
Prev Close
Rs619.70
Open
Rs623.00
Day's High
Rs633.40
Day's Low
Rs619.00
Volume
12,293,203
Avg. Vol
6,109,204
52-wk High
Rs633.40
52-wk Low
Rs435.00

Select another date:

Tue, Aug 14 2018

UPDATE 1-India's Sun Pharma Q1 profit beats estimates as U.S. sales climb

* Stock top gainer on NSE index (Adds details on U.S. and India sales, share movement)

India's Sun Pharma quarterly profit beats estimates

Aug 14 India's largest drugmaker Sun Pharmaceutical Industries Ltd posted a first-quarter profit on Tuesday, beating street estimates.

India's Sun Pharma says U.S. FDA clears Halol plant

MUMBAI, June 12 India's largest drugmaker Sun Pharmaceutical Industries Ltd said on Tuesday the U.S. Food and Drug Administration (FDA) cleared its Halol drug plant, which had been under supply restrictions due to quality control failures.

Indian shares recover from early losses to end flat

* NSE index ended 0.01 pct down, BSE index closed 0.05 pct lower

Indian shares end higher; banks, oil firms gain

May 28 Indian shares ended higher for a third session on Monday, as lower crude prices and a firmer rupee lifted sentiment, with financial and oil stocks accounting for much of the gains.

Indian shares gain as crude oil slips; Sun Pharma top gainer

May 28 Indian equities gained for a third straight session on Monday as a sharp drop in crude prices and a recovery in the rupee boosted sentiment, while shares of Sun Pharmaceutical Industries saw their best day in over three years on strong fourth-quarter results.

UPDATE 2-India's Sun Pharma warns U.S. pricing pressure to hit 2019 profit

* Plans to reduce "unviable" generics research (Adds managing director comments from conference call)

India's Sun Pharma Industries Q4 profit up 7 pct, beats estimates

May 25 Sun Pharmaceutical Industries Ltd , India's largest drugmaker, posted fourth-quarter net profit way above expectations.

BRIEF-Sun Pharmaceutical Industries' Unit Raises Stake In Ranbaxy Malaysia

* UNIT RAISED STAKE IN RANBAXY MALAYSIA VIA FURTHER PURCHASE OF 394,404 SHARES OF RANBAXY MALAYSIA

BRIEF-Sun Pharmaceutical Industries Gets U.S. FDA Nod Of ILUMYA (Tildrakizumab-Asmn)

* CO GETS U.S. FDA APPROVAL OF ILUMYA (TILDRAKIZUMAB-ASMN) FOR TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS Source text - http://bit.ly/2HRX8j1 Further company coverage:

Select another date: